Dr. Henry Miller, a former FDA deputy commissioner, used to be a big fan of the New York Times' coverage of science and medicine. But no longer. He takes issue with an editorial that accuses the agency of reducing its scrutiny of new drugs. Dr. Miller explains why the Times is off-base: the development of precision medicine.
Henry Miller
ACSH medical director Dr. Gilbert Ross and ACSH friend, the Hoover Institution s Dr. Henry Miller, have taken to Forbes.com to discuss the current state of Alzheimer s disease (AD) in our country. The article imparts a thorough discussion on the state of diagnostics, treatment and research of a disease whose prevalence is on the rise in America. The writers point out that in comparison with higher profile diseases (such as heart dis
The always-excellent Henry Miller does not disappoint in his latest op-ed about the impact of junk science on all of us. It is sad, but